271 related articles for article (PubMed ID: 28919712)
21. New options and controversies in the management of chemotherapy-induced nausea and vomiting.
Koth SM; Kolesar J
Am J Health Syst Pharm; 2017 Jun; 74(11):812-819. PubMed ID: 28396308
[TBL] [Abstract][Full Text] [Related]
22. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Zhang Y; Yang Y; Zhang Z; Fang W; Kang S; Luo Y; Sheng J; Zhan J; Hong S; Huang Y; Zhou N; Zhao H; Zhang L
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27795228
[TBL] [Abstract][Full Text] [Related]
23. Rolapitant (Varubi) for prevention and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2016 Feb; 58(1487):17-8. PubMed ID: 26812124
[No Abstract] [Full Text] [Related]
24. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K; Jahn F; Aapro M
Ann Oncol; 2015 Jun; 26(6):1081-1090. PubMed ID: 25755107
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
26. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
27. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
28. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Navari RM
Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
Wang X; Wang J; Zhang ZY; Kansra V
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):850-860. PubMed ID: 31418538
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
[TBL] [Abstract][Full Text] [Related]
32. Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.
Abdel-Rahman O; Fouad M
Future Oncol; 2016 Mar; 12(6):871-9. PubMed ID: 26806790
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
Navari RM
Drugs; 2009; 69(5):515-33. PubMed ID: 19368415
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
35. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
[TBL] [Abstract][Full Text] [Related]
36. Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.
Rapoport BL
Front Pharmacol; 2017; 8():19. PubMed ID: 28194109
[TBL] [Abstract][Full Text] [Related]
37. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
[TBL] [Abstract][Full Text] [Related]
38. Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting: review and focus on the Belgian situation.
Van den Brande J; Brouwer A; Peeters M
Acta Gastroenterol Belg; 2014 Jun; 77(2):240-8. PubMed ID: 25090823
[TBL] [Abstract][Full Text] [Related]
39. Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.
Barbour S; Smit T; Wang X; Powers D; Arora S; Kansra V; Aapro M; Herrstedt J
Ann Oncol; 2017 Jun; 28(6):1268-1273. PubMed ID: 28327932
[TBL] [Abstract][Full Text] [Related]
40. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
Morrow GR; Navari RM; Rugo HS
Clin Adv Hematol Oncol; 2014 Mar; 12(3 Suppl 9):1-14; quiz 15. PubMed ID: 24874107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
